MPO-001 Lempo Treatment for Pulmonary Arterial Hypertension
The underlying pathological hallmarks of PAH include pulmonary arterial endothelial cell (EC) dysfunction, pulmonary artery EC and smooth muscle cell (SMC) proliferation, excessive vasoconstriction, RV hypertrophy, fibrosis & inflammation and in-situ thrombosis.
Pulmonary Arterial Hypertension (PAH) is a rare, progressive disorder with no cure and poor life expectancy. With a prevalence rate of 10-52 cases /million worldwide, it can affect people of all ages, predominantly young women with a female to male ratio of 67% to 33%, respectively.
PAH is defined as ‘Group 1’ in the World Health Organization (WHO) clinical classification of pulmonary hypertension (PH) and is characterized by high blood pressure in the pulmonary arteries. The condition begins with arteries between the heart and the lungs becoming narrow or blocked, making it difficult for blood to flow through them, cutting supply to lungs. As a result stress on the right side of the heart increases to facilitate higher blood flow to lungs leading to weakened heart muscle and eventual heart failure.
Current treatments focus each on a specific disease progression pathway, providing temporary relief of the PAH symptoms. Combination therapy has shown to be effective for some patients (especially those in “low risk” criteria) in clinical trials. Yet, a substantial proportion of patients with PAH has clinical worsening despite combination therapy. Following inadequate clinical response and advancing from a low risk criteria into moderate or high risk, patients are put on the